Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorGERBAUD, Edouard
dc.contributor.authorBOUCHARD DE LA POTERIE, Ambroise
dc.contributor.authorBAUDINET, Thomas
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorMONTAUDON, Michel
hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
dc.contributor.authorBEAUVIEUX, Marie Christine
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorLEMAITRE, Anne-Iris
dc.contributor.authorCETRAN, Laura
dc.contributor.authorSEGUY, Benjamin
dc.contributor.authorPICARD, François
dc.contributor.authorVELAYOUDOM, Fritz-Line
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorOUATTARA, Alexandre
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKABORE, Remi
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorCOSTE, Pierre
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorDOMINGUES DOS SANTOS, Pierre
dc.contributor.authorCATARGI, Bogdan
dc.date.accessioned2022-04-07T12:11:04Z
dc.date.available2022-04-07T12:11:04Z
dc.date.issued2022-03-11
dc.identifier.issn2077-0383en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136608
dc.description.abstractEn(1) Background: Hyperglycaemia and hypoglycaemia are both emerging risk factors for cardiovascular disease. Nevertheless, the potential effect of glycaemic variability (GV) on mid-term major cardiovascular events (MACE) in diabetic patients presenting with acute heart failure (AHF) remains unclear. This study investigates the prognostic value of GV in diabetic patients presenting with acute heart failure (AHF). (2) Methods: this was an observational study including consecutive patients with diabetes and AHF between January 2015 and November 2016. GV was calculated using standard deviation of glycaemia values during initial hospitalisation in the intensive cardiac care unit. MACE, including recurrent AHF, new-onset myocardial infarction, ischaemic stroke and cardiac death, were recorded. The predictive effects of GV on patient outcomes were analysed with respect to baseline characteristics and cardiac status. (3) Results: In total, 392 patients with diabetes and AHF were enrolled. During follow-up (median (interquartile range) 29 (6-51) months), MACE occurred in 227 patients (57.9%). In total, 92 patients died of cardiac causes (23.5%), 107 were hospitalised for heart failure (27.3%), 19 had new-onset myocardial infarction (4.8%) and 9 (2.3%) had an ischaemic stroke. Multivariable logistic regression analysis showed that GV > 50 mg/dL (2.70 mmol/L), age > 75 years, reduced left ventricular ejection fraction (LVEF < 30%) and female gender were independent predictors of MACE: hazard ratios (HR) of 3.16 (2.25-4.43; < 0.001), 1.54 (1.14-2.08; = 0.005), 1.47 (1.06-2.07; = 0.02) and 1.43 (1.05-1.94; = 0.03), respectively. (4) Conclusions: among other well-known factors of HF, a GV cut-off value of >50 mg/dL was the strongest independent predictive factor for mid-term MACE in patients with diabetes and AHF.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/us/
dc.subjectARTICLE CLINIQUE
dc.subject.enDiabetes
dc.subject.enGlycaemic variability
dc.subject.enAcute heart failure
dc.subject.enMajor adverse cardiovascular event
dc.title.enGlycaemic Variability and Hyperglycaemia as Prognostic Markers of Major Cardiovascular Events in Diabetic Patients Hospitalised in Cardiology Intensive Care Unit for Acute Heart Failure.
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/jcm11061549en_US
dc.subject.halSciences du Vivant [q-bio]en_US
dc.identifier.pubmed35329874en_US
bordeaux.journalJournal of Clinical Medicineen_US
bordeaux.volume11en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219
bordeaux.hal.laboratoriesCentre de Recherche Cardio-Thoracique de Bordeaux (CRCTB) - U1045
bordeaux.hal.laboratoriesCentre de Résonance Magnétique des Systèmes Biologiques (CRMSB) - UMR 5536
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCNRS
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-03634108
hal.version1
hal.date.transferred2022-04-22T09:09:18Z
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Clinical%20Medicine&rft.date=2022-03-11&rft.volume=11&rft.issue=6&rft.eissn=2077-0383&rft.issn=2077-0383&rft.au=GERBAUD,%20Edouard&BOUCHARD%20DE%20LA%20POTERIE,%20Ambroise&BAUDINET,%20Thomas&MONTAUDON,%20Michel&BEAUVIEUX,%20Marie%20Christine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée